Browse
Submit Data
Databases
API
Help

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer

ABSTRACT: RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome. PURPOSE: This phase III randomized trial is studying pyridoxine to see how well it works compared to a placebo in preventing hand-foot syndrome in patients who are receiving capecitabine for advanced colorectal cancer or breast cancer.

DISEASE(S): Palmar-plantar Erythrodysesthesia,Colon Cancer,Colorectal Cancer,Hand-foot Syndrome,Colorectal Neoplasms,Breast Neoplasms,Hand-foot Syndrome In Patients With Advanced Colorectal Or Breast Cancer,Breast Cancer

PROVIDER: 2046490 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer

Project description:RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with capecitabine may kill more tumor cells. Celecoxib may prevent or lessen hand-foot syndrome caused by capecitabine. PURPOSE: This randomized phase III trial is studying how well celecoxib works in preventing hand/foot syndrome caused by capecitabine in patients with metastatic breast or colorectal cancer.

| 2027398 | ecrin-mdr-crc

MicroRNA of exosome in Hand, foot and mouth disease serum samples

Project description:The some biomarkers can be found by pairwise comparison. They can distinguish between extremely severe Hand,foot and mouth disease and mild Hand,foot and mouth disease,moreover,they can applied to diagnose extremely severe Hand,foot and mouth disease mild Hand,foot and mouth disease vs.control; extremely severe Hand,foot and mouth disease vs.control; extremely severe Hand,foot and mouth disease vs.mild Hand,foot and mouth disease,verification by qRT-PCR

2013-11-27 | E-GEOD-52780 | biostudies-arrayexpress

MicroRNA of exosome in Hand, foot and mouth disease serum samples

2013-11-27 | GSE52780 | GEO

Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer

Project description:RATIONALE: Hand foot syndrome may be treated or reduced by soaking Traditional Chinese Medicine Formula LC09 in patients receiving capecitabine for colorectal and/or breast cancer. PURPOSE: This randomized phase III trial is studying soaking Traditional Chinese Medicine Formula LC09 to see how well they work compared to placebos in preventing hand-foot syndrome in patients who are receiving capecitabine for colorectal or breast cancer.

| 2216854 | ecrin-mdr-crc

A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).

Project description:This 3 arm study will compare the prophylactic effect of topical corticosteroids, Bepantol or placebo on hand-foot syndrome in patients receiving Xeloda for treatment of metastatic breast cancer, metastatic colorectal cancer or adjuvant treatment of colorectal cancer. Patients who have been receiving oral Xeloda for at least 5 days will be randomized to receive prophylactic treatment with either placebo, topical corticosteroids or Bepantol. The anticipated time on study treatment is until disease progression or development of hand-foot syndrome, and the target sample size is 500+ individuals.

| 2054107 | ecrin-mdr-crc

Structured teaching module for Hand foot syndrome Colorectal cancer

Project description:Primary outcome(s): To study the effect of Structured Teaching module (STM) on incidence and severity of Hand Foot syndrome among patients receiving Capecitabine based chemotherapy for colorectal cancer at a Tertiary Cancer Care CentreTimepoint: 2 year

| 2577989 | ecrin-mdr-crc

Large-scale outbreak of hand-foot and mouth disease, France, 2021

Project description:Large-scale outbreak of hand-foot and mouth disease, France, 2021

| PRJEB48181 | ENA

The development of new preventive measures and therapeutic methods in the management of hand-foot syndrome by regorafenib

Project description:Interventions: Effectiveness of prevention of hand-foot syndrome associated with Regorafenib by using aluminum chloride and wound dressing Primary outcome(s): Incidence of Grade 3 HFS Study Design: single arm study, open(masking not used), historical control, single assignment, prevention purpose

| 2613973 | ecrin-mdr-crc

The development of new preventive measures and therapeutic methods in the management of hand-foot syndrome by multi-kinase inhibitors regorafenib

Project description:Interventions: 12 weeks /Application of aluminium chloride ointment once a day and application of wound dressing after the presentation of grade 1 hand-foot syndrome Primary outcome(s): Incidence of Grade 3 HFS Study Design: Single arm Non-randomized

| 2647838 | ecrin-mdr-crc

Chinese medicine in postoperative adjuvant chemotherapy (Capecitabine therapy) for colorectal cancer: Examination of prevention of hand-foot syndrome by the prophylactic administration of Eppikajutsutou (clinical phase II study)

Project description:Interventions: Capecitabine + Eppikajutsutou group One course of Capecitabine: Daily oral administration of Capecitabine (Xeloda) dose according to the body surface area twice a day for 14 days within 30 minutes after the breakfast and the supper, and a rest for seven days afterwards. Total 8 courses are performed. Eppikajutsutou: Daily oral administration during Capecitabine therapy Its dose is 7.5g divided in three times/day, before a meal or inter cibos. Capecitabine + Vitamin B6 group One course of Capecitabine: It is the same as intervention 1. Vitamin B6: Daily oral administration during Capecitabine therapy Its dose is 60mg divided in three times/day, after a meal. Primary outcome(s): Incidence rate of hand-foot syndrome of Grade2 or more Study Design: Parallel Randomized

| 2621335 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data